Pseudomonas aeruginosa Does NOT Respond to Cefdinir
Cefdinir is inactive against Pseudomonas aeruginosa and should never be used to treat infections caused by this organism. This is explicitly stated in the FDA drug label and confirmed across multiple sources 1.
Why Cefdinir Fails Against Pseudomonas
The FDA-approved prescribing information for cefdinir clearly states: "Cefdinir is inactive against most strains of Enterobacter spp., Pseudomonas spp., Enterococcus spp., penicillin-resistant streptococci, and methicillin-resistant staphylococci" 1. This is a fundamental limitation of the drug's antimicrobial spectrum.
Mechanism of Inactivity
- Intrinsic resistance: Pseudomonas aeruginosa possesses intrinsic resistance mechanisms that render cefdinir ineffective, including decreased permeability and β-lactamase production that hydrolyzes cefdinir 1
- Research confirmation: Multiple in vitro studies demonstrate that cefdinir has "little activity against P. aeruginosa" with MIC values consistently in the resistant range 2, 3, 4
- Quality control testing: Laboratory standards specifically exclude P. aeruginosa from cefdinir susceptibility testing panels, using it only as a control organism for other antibiotics 5
What DOES Work Against Pseudomonas
When treating Pseudomonas aeruginosa infections, the appropriate antipseudomonal agents include:
For Standard Pseudomonas Infections:
- Antipseudomonal cephalosporins: Ceftazidime, cefepime 6, 7
- Antipseudomonal penicillins: Piperacillin-tazobactam 6, 7
- Carbapenems: Meropenem (preferred, up to 6g daily), imipenem 6, 7
- Fluoroquinolones: Ciprofloxacin, levofloxacin 6, 8, 7
- Aminoglycosides: Gentamicin, tobramycin, amikacin 6, 7
For Difficult-to-Treat Resistant Pseudomonas (DTR-PA):
Novel β-lactam agents are first-line: Ceftolozane-tazobactam and ceftazidime-avibactam are currently the preferred options, with imipenem-cilastatin-relebactam and cefiderocol as alternatives 9. Colistin-based therapy remains an option when other agents fail.
Critical Clinical Pitfall
Never empirically use cefdinir for suspected Pseudomonas infections. This is a common error in clinical practice, particularly in:
- Nosocomial pneumonia
- Healthcare-associated infections
- Patients with structural lung disease (bronchiectasis, cystic fibrosis)
- Neutropenic patients
- Patients with indwelling devices
If Pseudomonas coverage is needed, you must select from the antipseudomonal agents listed above. Cefdinir's spectrum is limited to susceptible Gram-positive cocci (methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and select Gram-negative organisms (Haemophilus influenzae, Moraxella catarrhalis) 1.